Brokerages forecast that Vistagen Therapeutics Inc (NASDAQ:VTGN) will report earnings per share of ($0.30) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics posted earnings of ($0.24) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 25%. The business is scheduled to announce its next earnings results on Monday, February 11th.
On average, analysts expect that Vistagen Therapeutics will report full year earnings of ($1.10) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will post earnings of ($1.48) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Vistagen Therapeutics.
Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Monday, October 29th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.13).
Several equities research analysts have recently issued reports on VTGN shares. Maxim Group set a $6.00 price objective on Vistagen Therapeutics and gave the company a “buy” rating in a research note on Monday, August 6th. Oppenheimer set a $6.00 price objective on Vistagen Therapeutics and gave the company a “buy” rating in a research note on Friday, August 24th. Zacks Investment Research raised Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Thursday, August 30th. Finally, ValuEngine raised Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $8.30.
Shares of NASDAQ:VTGN traded down $0.04 during trading on Friday, hitting $2.00. The company had a trading volume of 102,458 shares, compared to its average volume of 557,919. The firm has a market capitalization of $64.29 million, a price-to-earnings ratio of -1.80 and a beta of -1.53. Vistagen Therapeutics has a one year low of $0.69 and a one year high of $2.65.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Further Reading: Cost of Capital
Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.